Program
lacutoclax
Also written as “LP-108”, “Lacutoclax” and “Lacutoclax+Rocbrutinib”.
Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by Lupeng Pharmaceutical.
Furthest: phase 2, since May 20, 20264 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lupeng Pharmaceutical | 43 open or running | phase 2since May 20, 2026 | Oct 18, 2019 | Dec 31, 2027phase 1 · NCT05641259 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 18, 2019First study: phase 1 study in RecurrenceFirst studyNCT04139434 · 32 enrolled · United States, Spain
- Nov 17, 2022Phase 1 study in Leukemia, Myeloid, AcuteNCT05641259 · 198 planned · China
- May 20, 20262 phase 2 studiesPhase 2 reachedNCT07609862, NCT07609823
Ahead
- Dec 31, 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT05641259
- Mar 30, 2028Primary completion: phase 2 study in RecurrenceNCT07609823
- Jun 30, 2029Primary completion: phase 2 study in Lymphoma, Mantle-CellNCT07609862
TargetBeta
BCL2 →read by rule
“The goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).”study text, by rule · the study
Other programs on BCL2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| venetoclaxrule | AbbVie | phase 4 | 83 |
| Bcl-2 Inhibitor TQB3909 | Sino Biopharmaceutical | phase 3 | 8 |
| surzetoclax | AbbVie | phase 2 | 3 |
| 400mg of TQB3909 tablets | Sino Biopharmaceutical | phase 2 | 1 |
| surzetoclax | AbbVie | phase 1 | 2 |
| FXS0683 | Fosun Pharma | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07609862Lymphoma, Mantle-Cell · China | 2 | Recruiting | Jun 30, 2029 | 92 |
| NCT07609823Recurrence · China | 2 | Recruiting | Mar 30, 2028 | 75 |
| NCT05641259Leukemia, Myeloid, Acute · China | 1 | Recruiting | Dec 31, 2027 | 198 |
| NCT04139434Recurrence · United States, Spain | 1 | Completed | Dec 19, 2025 | 32 |
How it is read
Names in the registry
- “LP-108”, 2 entries
- “Lacutoclax”, 1 entry
- “Lacutoclax+Rocbrutinib”, 1 entry
- “LP-108 and azacitidine”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Lymphoma, Mantle-Cell, 1 study
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.